Peggy Hwang

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 300 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Mark Sulkowski, Christophe Hézode, Jan Gerstoft et al. · The Lancet · 2014 · 280 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or Without Pembrolizumab for Gastric Cancer

Yung‐Jue Bang, Eric Van Cutsem, Charles S. Fuchs et al. · Future Oncology · 2019 · 171 citations · Full text

Medicine, Oncology, Perioperative Medicine +14

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension

Sukrut Shah, Anne Hermanowski‐Vosatka, Kendra Gibson et al. · Journal of the American Society of Hypertension · 2011 · 92 citations

Medicine, Endocrinology, Pharmacology +8

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

Ira M. Jacobson, Eric Lawitz, Paul Y. Kwo et al. · Gastroenterology · 2017 · 89 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17